FIG. 3.

Contribution of the components of the combined-treatment regimen to prolonged βgal expression in the alveolar epithelium. Results are the mean ± SD of the numerical score for βgal expression based on a scale of 0 to 5. Data were derived from two experiments with two to four mice per time point per group, except for the MR1 group, which was one experiment with one or two mice per time point. The AdCTLAIg group received Ad.RSV-muCTLA4Ig intratracheally along with Ad.RSV-βgal on day 0; the Ad+IP muCTLA4Ig group received Ad.RSV-muCTLA4Ig intratracheally along with Ad.RSV-βgal on day 0 and recombinant muCTLA4Ig IP on days −1, 2, and 7; the MR1 group received MR1 on days −1, 2, and 7; the control and combined-treatment regimens are described in the legend to Fig. 2.